Needham & Company LLC Boosts Esperion Therapeutics, Inc. (ESPR) Price Target to $72.00

Esperion Therapeutics, Inc. (NASDAQ:ESPR) had its price target increased by Needham & Company LLC from $58.00 to $72.00 in a report released on Tuesday. They currently have a positive rating on the biopharmaceutical company’s stock.

ESPR has been the subject of several other research reports. ValuEngine upgraded shares of Esperion Therapeutics from a sell rating to a hold rating in a research note on Friday, June 2nd. BidaskClub upgraded shares of Esperion Therapeutics from a hold rating to a buy rating in a research note on Sunday, June 25th. Zacks Investment Research downgraded shares of Esperion Therapeutics from a hold rating to a sell rating in a research note on Monday, May 1st. Deutsche Bank AG began coverage on shares of Esperion Therapeutics in a research note on Friday, June 23rd. They issued a buy rating and a $48.00 price target for the company. Finally, Citigroup Inc. restated a buy rating on shares of Esperion Therapeutics in a research note on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $42.51.

Esperion Therapeutics (ESPR) traded up 2.47% on Tuesday, hitting $49.33. The stock had a trading volume of 912,599 shares. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.38. The stock’s market cap is $1.11 billion. The firm’s 50 day moving average price is $47.09 and its 200-day moving average price is $35.27.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by $0.25. During the same period last year, the business posted ($0.62) EPS. On average, analysts forecast that Esperion Therapeutics will post ($7.29) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/08/12/needham-company-llc-boosts-esperion-therapeutics-inc-espr-price-target-to-72-00.html.

Institutional investors have recently modified their holdings of the company. US Bancorp DE increased its position in shares of Esperion Therapeutics by 1.1% in the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after buying an additional 104 shares during the last quarter. American International Group Inc. increased its position in shares of Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 584 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock worth $1,387,000 after buying an additional 921 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Esperion Therapeutics by 3.0% in the second quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after buying an additional 1,148 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Esperion Therapeutics by 5.3% in the second quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after buying an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 85.20% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply